AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 OCT 18 - (NewsRx.com & NewsRx.net) -- Fosamax Once Weekly (alendronate sodium) increased bone mineral density (BMD) more than Actonel Once-a-Week (risedronate) with similar tolerability, according to results of the Fosamax Actonel Comparison Trial (FACT) .
This is the first U.S. head-to-head study comparing U.S. Food and Drug Administration-approved once-weekly osteoporosis treatments in postmenopausal women with osteoporosis.
In this study, Fosamax provided greater increases in BMD at all sites measured as early as 6 months, and lowered levels of biochemical markers of bone turnover further within the normal pre-menopausal range than Actonel within 3 months. Reducing and stabilizing bone turnover, which leads to increased bone density, are important factors in improving bone strength in patients with osteoporosis.
The results of FACT, which was a 12-month study, were announced online on September 28, 2004, in the Journal of Bone and Mineral Research and were presented on October 1, 2004, at the American Society for Bone Mineral Research meeting in Seattle, Washington. A 12-month extension of this double-blind study, and a second similarly designed study, are currently underway.
Fosamax is the only medicine approved by the U.S. Food and Drug Administration for the treatment of osteoporosis to reduce the risk of both spine and hip fractures in postmenopausal women. Fosamax is the most prescribed medicine for the treatment of osteoporosis, according to Merck, which makes the drug.